Entrepreneurial patent-holder CEO with a PhD and MBA has over twenty-two years of success with overall operational responsibility and direct oversight of biotech company and several academic healthcare departments delivering lifesaving research and biomedical innovations within the oncology, neuroscience, biotechnology, and infectious disease arenas. Maximizes revenue by securing funding to further research, train staff and students to accept clinical trial assignments, oversee intellectual property and patents, and manage project costs. Sought-after speaker and author, delivering groundbreaking outcomes during times of health crisis and within the most challenging environments.
Serves as a trusted advisor and confidante to healthcare executives, funding agencies, academic and hospital staff and students, and fellow consultants. Inspires the identification of medical breakthroughs and the research for answers to complex problems by collaborating with key stakeholders. Transforms underperforming individuals and groups into dedicated teams driven to achieve aggressive goals and objectives.
Doctor of Philosophy (Ph.D.) Major: Medical Microbiology & Immunology (University of Gothenburg, Sweden)
Most Memorable Moment:
My thesis addressed the regulatory role of the biogenic amine histamine on natural killer (NK) cell functions. Importantly, these studies helped form the basis for clinical trials of combined histamine and interleukin-2 (IL-2), a drug now known as Ceplene, that is currently prescribed for patients with metastatic melanoma and high-risk acute myeloid leukemia (AML).
Founder, President and Chief Scientific Officer|
Exordium Biotechnology LLC
From February 2020 to Current • 6 year(s)
Leading biotechnology company focused on sustainable microbe solutions, managing 68 staff and raised $20M Series A funding.
Board of Directors and Scientific Advisory Board Member|
Swedish Herbal Institute
From May 2015 to Current • 11 year(s)
Providing strategic direction for biopharmaceutical company developing herbal-based products with focus on adaptogens.
Founder, President and Chief Executive Officer|
NampEVA BioTherapeutics LLC
From May 2010 to Current • 16 year(s)
Leading biopharmaceutical company focused on affordable cancer care medicines, managing 25 staff and securing R&D funding including $3.75M licensing agreement.
Board of Directors and Scientific Advisory Board Member|
Multimmune GmbH
From January 2010 to Current • 16 year(s)
Providing leadership in anti-heat shock protein 70 therapeutic development, collaborated on Phase II clinical trial resulting in $25M revenue increase.
Executive Director and Professor of Medicine|
University of Toledo College of Medicine
From February 2018 to October 2020 • 2 year(s)
Established Precision Therapeutics Proteogenomics Diagnostics Center on $5M budget, garnered $15.2M in revenue through clinical trials negotiations.
Consultant in Tumor Immunology and Scientific Director|
University of Texas MD Anderson Cancer Center
From June 2016 to February 2018 • 2 year(s)
Provided leadership in preclinical and clinical laboratory-based cancer treatments, achieved $3.9M revenue through pharmaceutical partnerships.
Scientific Director and Advisory Board Member|
Vitruvian BioMedical
From February 2012 to December 2016 • 4 year(s)
Provided leadership in CNS-based therapeutics development and advised on Alzheimer's Disease therapeutic vaccine development.
Head, Section of Translational Medicine|
Euro-Mediterranean Institute of Science and Technology
From March 2013 to October 2016 • 3 year(s)
Led R&D directions and drug development, established five virtual R&D labs resulting in $11M grant funding over three years.
Vice President for Research and Professor of Medicine|
University of Dammam and King Fahd University Hospital
From May 2014 to August 2016 • 2 year(s)
Established Department of Neuroscience, attained $22.5M revenue for cGMP manufacturing facility and led eight Phase I-III clinical trials.
Chairman and Professor of Medicine|
Morehouse School of Medicine and Grady Hospital
From October 2012 to May 2014 • 2 year(s)
Led 60+ faculty and staff as Department Chairman, achieved 45% reduction in ordering errors and $3.7M cost savings.
Chief Division of Investigative Pathology and Professor|
Texas A&M University and Baylor Scott & White Healthcare
From May 2005 to October 2012 • 7 year(s)
Served as Endowed Chair with $5.3M annual budget, awarded $5.6M NIH grant and developed innovative proteomics facility generating $250K annual revenue.
Deputy Chief and Assistant Professor|
University of Boston School of Medicine and Boston Medical Center
From April 2001 to April 2005 • 4 year(s)
Led Center for Molecular Stress Response and Scientific Director of Compound Development Laboratory.
Instructor in Radiation Oncology|
Dana-Farber Cancer Institute and Harvard Medical School
From December 1999 to November 2002 • 3 year(s)
Conducted radiation oncology research and clinical work.
Postdoctoral Research Associate|
Brigham and Women's Hospital and Harvard Medical School
From December 1998 to December 1999 • 1 year(s)
Conducted postdoctoral research in medical sciences.
Postdoctoral Research Assistant|
Schepen's Eye Institute and Harvard Medical School
From October 1996 to November 1998 • 2 year(s)
Conducted eye research and development projects.
Postdoctoral Research Fellow|
University of Miami Jackson Memorial Hospital
From May 1995 to September 1996 • 1 year(s)
Conducted postdoctoral research in medical sciences.
A very warm welcome to you. It is lovely to
have you among us. May you have a blessed,
constructive and prosperous day. Stay strong.
Tagged by
Ralph White on 09/09/2022
